About this policy
The comment period for the MolDX: Plasma-Based Genomic Profiling in Solid Tumors DL39230 Local Coverage Determination (LCD) began on 01/20/2022 and ended on 03/05/2022. The comments below were received from the provider community. The notice period for L39230 begins on 11/10/2022 and will become effective on 12/26/2022. Noridian received comments from 6 different commenters. Introduction to Responses Noridian appreciates the comments received from stakeholders during the open comment period on the proposed MolDX: Plasma-Based Genomic Profiling Local Coverage Determination (LCD). We reviewed the comments in their entirety. Submitted comments that cite published, peer-reviewed literature provide suitable evidence that may inform policy, while less rigorous comments (e.g., anecdotal, unpublished information not subject to peer review) are much less influential to policy determinations. NOTE: Noridian reviews all submitted comments; however, MACs may choose to consolidate similar thematic comments, redact, or withhold certain submissions (or portions thereof) such as those containing private or proprietary information, or inappropriate language. This may result in discrepancies between the number of comments in the article and the actual number of comments received.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.